@article{fdi:010070020,
  title = {{P}redictors of delayed culture conversion among {U}gandan patients},
  author = {{A}twine, {D}. and {O}rikiriza, {P}. and {T}aremwa, {I}. and {A}yebare, {A}. and {L}ogoose, {S}. and {M}wanga-{A}mumpaire, {J}. and {J}indani, {A}. and {B}onnet, {M}aryline},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground: {E}stimates of month-2 culture conversion, a proxy indicator of tuberculosis ({TB}) treatment efficacy in phase-2 trials can vary by culture-type and geographically with lower rates reported among {A}frican sites. {T}he sub-study aimed at comparing {TB} detection rates of different culture media, within and across rifampicin-based regimens ({R}10, 15 and 20 mg/{K}g) over a 6-month treatment follow-up period, and to establish predictors of month-2 culture non-conversion among {HIV}-negative {TB} patients enrolled at {RIFATOX} trial site in {U}ganda. {M}ethods: {U}nlike in other {R}ifatox {T}rial sites, it is only in {U}ganda were {L}owenstein-{J}ensen ({LJ}) and {M}ycobacteria growth indicator tube ({MGIT}) were used throughout 6-months for treatment monitoring. {C}onversion rates were compared at month-2, 4 and 6 across cultures and treatment-type. {B}inomial regression analysis performed for predictors of month-2 non-conversion. {R}esults: {O}f the 100 enrolled patients, 45% had converted based on combined {LJ} and {MGIT} by month-2, with no significant differences across treatment arms, p = 0.721. {LJ} exhibited higher conversion rates than {MGIT} at month-2 (58.4% vs 56.0%, p = 0.0707) and month-4 (98.9% vs 88.4%, p = 0.0391) respectively, more so within the high-dose rifampicin arms. {A}ll patients had converted by month-6. {T}ime-to-{TB} detection ({TTD}) on {MGIT} and social service jobs independently predict month-2 non-conversion. {C}onclusion: {T}he month-2 culture conversion used in phase 2 clinical trials as surrogate marker of treatment efficacy is influenced by the culture method used for monitoring mycobacterial response to {TB} treatment. {T}herefore, multi-centric {TB} therapeutic trials using early efficacy endpoint should use the same culture method across sites. {T}he {T}ime-to-detection of {MTB} on {MGIT} prior to treatment and working in {S}ocial service jobs bear an increased risk of culture non-conversion at month-2.},
  keywords = {{D}elayed culture conversion ; {E}fficacy ; {HIV}-negative {TB} patients ; {T}ime-to-detection ; {T}reatment failure ; {OUGANDA}},
  booktitle = {},
  journal = {{BMC} {I}nfectious {D}iseases},
  volume = {17},
  numero = {},
  pages = {art. 299 [8 p.]},
  ISSN = {1471-2334},
  year = {2017},
  DOI = {10.1186/s12879-017-2335-7},
  URL = {https://www.documentation.ird.fr/hor/fdi:010070020},
}